All In MedTech

Device Trial Radar · NCT05451862

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma; a Prospective, Single-arm, Open Label, Multicenter Phase II Study: HOMIE-166.

Last checked: Nov 20, 2026Latest source record: Aug 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

6

Actual

Start

Aug 21, 2023

Primary completion

May 27, 2025

Study completion May 27, 2025

Sponsor

Lead sponsor
Terumo Europe N.V.Public (4543.T)
Sponsor type
Industry
First posted
Jul 11, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

166Ho-TARE is a promising modality for the treatment of HCC, given the unique characteristics of holmium, allowing careful patient selection and personalized dosimetry treatment planning. Further clinical evidence is needed to evaluate the safety and efficacy of 166Ho-TARE in the treatment of HCC patients with limited tumor burden, well preserved liver function and performance status and ineligible for liver transplantation and/or liver resection. This study will also provide further evidence on the dose-response relationship of 166Ho-TARE in (early) HCC.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • Holmium-166 treatmentDevice

    Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.

  • Holmium-166 work-upDevice

    Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. confirmed Objective Response Rate (ORR) by localized mRECISTTime frame: 5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Universitätsklinikum Augsburg

    Augsburg, Germany

  • LMU Klinikum

    Munich, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.